| 平喘方联合孟鲁司特钠治疗儿童支气管哮喘的临床疗效观察 |
| 投稿时间：2024-05-14 修订日期：2024-09-18 点此下载全文 |
| 引用本文：陈春娟,郑志新,李骊.平喘方联合孟鲁司特钠治疗儿童支气管哮喘的临床疗效观察[J].药学实践杂志,2024,42(12):524~527,532 |
| 摘要点击次数: 163 |
| 全文下载次数: 401 |
|
|
| 中文摘要:目的 探讨平喘方联合孟鲁司特钠治疗儿童支气管哮喘的临床疗效。方法 选取2022年5月至2023年12月宝鸡市妇幼保健院收治的102例支气管哮喘患者，据简单随机法分为对照1组（孟鲁司特钠治疗，n=34）、对照2组（平喘方治疗，n=34）及观察组（平喘方联合孟鲁司特钠治疗，n=51），均持续治疗21 d。评估3组临床疗效。于治疗前后对比3组中医证候积分、炎症因子[白细胞介素（IL）-4、IL-17、干扰素（IFN）-γ、转化生长因子-β1（TGF-β1）、免疫球蛋白（Ig）E]及儿童呼吸和哮喘控制测试（TRACK）评分；记录不良反应。结果 与对照1组和对照2组相比，观察组总有效率更高（P<0.05）。治疗后观察组（喉中痰鸣、气粗息涌、咳呛阵作）中医证候积分与对照1组和对照2组相比均更低（P<0.05）。治疗后，观察组IL-4、IL-17、TGF-β1及IgE水平均低于对照1组和对照2组，IFN-γ水平及TRACK评分均高于对照1组和对照2组（P<0.05）。3组不良反应对比无差异（P>0.05）。结论 平喘方联合孟鲁司特钠用于治疗支气管哮喘患者可提高临床疗效，利于减轻炎症反应，缓解病情，且具安全性。 |
| 中文关键词:平喘方 孟鲁司特钠 支气管哮喘 炎症因子 |
| |
| Clinical curative effect of Pingchuan prescription combined with montelukast sodium on patients with bronchial asthma |
|
|
| Abstract:Objective To explore the clinical curative effect of Pingchuan prescription combined with montelukast sodium on patients with bronchial asthma. Methods A total of 102 patients with bronchial asthma admitted to the hospital were enrolled between May 2022 and December 2023. According to simple randomization method, they were divided into control 1 group （montelukast sodium，n=34）, control 2 group （Pingchuan prescription，n=34） and observation group （Pingchuan prescription combined with montelukast sodium，n=51）. All patients were treated for 21 d. The clinical curative effect in the three groups was evaluated. The scores of TCM syndromes, inflammatory factors [interleukin（IL）-4, IL-17, interferon（IFN）-γ, transforming growth factor-β1（TGF-β1）, immunoglobulin（Ig）E] and scores of the test for respiratory and asthma control in kids （TRACK） in the three groups were compared before and after treatment. The adverse reactions were recorded. Results Compared with control 1 group and control 2 group, total response rate was higher in observation group （P<0.05）. After treatment, scores of TCM syndromes （wheezing due to phlegm in throat, tachypnea, choking）in observation group were lower than those in control 1 group and control 2 group （P<0.05）. After treatment, levels of IL-4, IL-17, TGF-β1 and IgE in observation group were lower than those in control 1 group and control 2 group, while IFN-γ level and TRACK score were higher than those in control 1 group and control 2 group （P<0.05）. There was no difference in adverse reactions among the three groups （P>0.05）. Conclusion Pingchuan prescription combined with montelukast sodium could improve clinical curative effect in patients with bronchial asthma, which was beneficial to alleviate inflammatory response and disease severity, with certain safety. |
| keywords:Pingchuan prescription montelukast sodium bronchial asthma inflammatory factor |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
|
|
|
